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Incubation of cholinergic synaptic vesicles purified from the electric organ of Torpedo ocellata with radio- 
labeled [D-Ala2, D-LeuS]-enkephalin results in its accumulation in the vesicles. Kinetic analysis of the initial 
rates of uptake reveals temperature-dependent saturation kinetics which are best fitted by a single transport 
system (KT = 12 f 2 pM and I’,,,,, = 0.85 + 0.24 pmol/mg protein per min). The specific rates and extents of 
[3H]-[D-Ala2, D-Leuq-enkephalin uptake, like those of [3H]acetylcholine uptake, are highest in the purified 
synaptic vesicles fraction. These findings suggest that Torpedo cholinergic synaptic vesicles contain an 
opioid peptide transporter. The physiological significance of this transporter is discussed in view of the re- 
cent observation that Torpedo nerve terminals contain an endogenous enkephalin-like peptide and pre- 
synaptic opiate receptors. 
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1. INTRODUCTION 
The recent findings that the cholinergic nerve 
terminals of the Torpedo electric organ contain an 
endogenous enkephalin-like peptide and that 
acetylcholine (ACh) release from these neurons is 
inhibited by morphine in a naloxone reversible 
fashion [l] suggest hat the efficacy of cholinergic 
transmission in Torpedo is modulated by en- 
dogenous opiates. 
In mammalian brain, enkephalin is derived from 
a propeptide which is synthesized in the cell body 
and packaged into vesicles. The propeptide is then 
processed by proteolytic cleavage during ax- 
oplasmic transport [2]. Recently, it has been shown 
that isolated brain nerve terminals (synaptosomes) 
and synaptic vesicles contain specific enkephalin 
transporters [3,4]. This suggests that in mam- 
malian brain enkephalinergic neurons also contain 
a recycling mechanism by which the released pep- 
tides may be replenished. The intraterminal com- 
partmentation and metabolism of the Torpedo 
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enkephalin-like peptide and its interaction with the 
life cycle of ACh have not yet been determined. 
This work investigated the possibility that 
Torpedo cholinergic synaptic vesicles take up and 
accumulate opioid peptides. The results obtained 
indicate that incubation of the vesicles with the 
stable enkephalin analog [3H]-[D-Ala2,D-Leu5]- 
enkephalin results in its uptake, via a saturable 
transporter, into the vesicles. This vesicular 
transporter may function together with the ACh 
carriers [5,6], in replenishing the vesicular contents 
following presynaptic stimulation. 
2. EXPERIMENTAL 
2.1. Purification of Torpedo electric organ 
synaptic vesicles 
Torpedo electric organs were excised from live 
T. ocellata during the spring and stored at - 70°C 
till use (up to 9 months). Synaptic vesicles were 
purified from frozen electric organs by differential 
and density gradient centrifugation and by 
permeation chromatography on a controlled pore 
glass beads column as described for freshly excised 
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tissue [7], except that the frozen electric organs 
were crushed with a pestle and mortar prior to 
thawing and homogenization. The purified synap- 
tic vesicles (fraction SV of [7]) were stored in liquid 
nitrogen for up to a month without any detectable 
decrease in their ACh content. 
2.2. Measurement of tH]-[D-Al&,D-Leu’J- 
enkephalin uptake into synaptic vesicles 
Prior to the experiment the vesicles were in- 
cubated for 16 h at 25°C in 0.8 M glycine, 50 mM 
Hepes (pH 7.4). This resulted in depletion of their 
endogenous neurotransmitter store. The vesicles 
were then washed by centrifugation (250000 x g 
for 1 h) and resuspended (0.2-0.3 mg protein/ml) 
in the above buffer. Uptake was initiated by a 1: 1 
dilution of the vesicles with 0.8 M glycine, 50 mM 
Hepes (pH 7.4) which contained [D-Ala*,D-Leu’]- 
enkephalin at the indicated concentration and 
[3H]-[D-Ala2,D-Leu’]-enkephalin (2 &i/ml). The 
reaction mixture also contained captopril (10 PM) 
and puromycin (50 fiM) which inhibit endogenous 
peptidase activities [8]. The amount of radioactivi- 
ty taken up by the vesicles was determined at the 
indicated time intervals by placing aliquots (20~1) 
of the reaction mixture on 0.45 pm Millipore filters 
(HAWP) and rapidly washing (3 x 2.5 ml) with ice 
cold buffer. The amount of radioactivity retained 
on the filter was then measured by scintillation 
spectrometry. 
Thin-layer chromatography (TLC) of the opioid 
peptides was performed as described by Altstein et 
al. [S]. Protein was determined as in [9]. 
3. RESULTS AND DISCUSSION 
Incubation of purified Torpedo synaptic vesicles 
with [3H]-[D-Ala2,D-Leu5]-enkephalin (2 FM) at 
25°C resulted in the accumulation of radiolabel in 
the vesicles (fig.1). Uptake was linear for up to 
15 min (0.14 f 0.04 pmol/mg protein per min; n = 
11) and then leveled off to a plateau (2.9 f 
0.6 pmol/mg protein per min; n = 8). When 
vesicles preloaded with [3H]-[D-Ala2,D-Leu5]- 
enkephalin were subjected to a lOO-fold dilution 
with water, about half the vesicle-associated 
radioactivity was lost within 1 min of the dilution 
(51 f 9% of the total; n = 3), whilst only a small 
fraction (11 k 7% of the total; n = 3) was released 
upon a similar dilution with isotonic buffer (fig.2). 
26 
LI / I 
;05wry 1 
0 10 20 30 40 50 60 70 
TIME (min) 
Fig. 1. Time course of [3H]-[D-AlaZ,D-Leu5]enkephalin 
uptake ([3H]-DADL-enkephalin) by cholinergic synaptic 
vesicles purified from the Torpedo electric organ. 
Uptake was measured at 2 ,YM by filtration at 25°C (0) 
and 4°C (0) as described in section 2. 
After 10 min of the addition of water there was a 
small increment in the amount of radioactivity lost 
from the vesicles (56 f 9% of the total; n = 2), 
whereas an increase in the loss of radioactivity (35 
f 3% of the total; n = 2) was observed with the 
isotonic buffer. Addition of Triton X-100 (O.l(r/o) 
to vesicles preloaded with [3H]-[D-Ala2,D-LeuS]- 
enkephalin resulted in the rapid loss of virtually all 
the vesicle-associated radioactivity (fig.2). These 
findings suggest hat the accumulated radiolabel is 
indeed transported into the vesicles. Analysis by 
TLC [8] of the material taken up by the vesicles, 
revealed that virtually all vesicle bound radioactivi- 
ty (>90%) cochromatographed with a [3H]-[D- 
Ala*,D-Let?]-enkephalin standard (not shown). 
Examination of the dependence of the initial 
rate of [3H]-[D-Ala2,D-Leu5]-enkephalin uptake 
(determined from the slope of the uptake curve 
during the first 15 min) on the ligand concentra- 
tion revealed that the rate of uptake saturated 
(fig.2) and that within the concentration range in- 
vestigated (2-30pM) the results were best fitted 
with a single transport system with KT = 12 f 2 PM 
and V,,,,, = 0.85 +- 0.24 pmol/mg protein per min 
(n = 3). Examination of the temperature 
dependence of the initial rate of [3H]-[D-Ala2,D- 
Let?]-enkephalin (2 PM) influx revealed that it was 
much slower (6-fold) at 4°C than at 25°C (fig.1). 
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Fig.2. The effect of hypotonic and isotonic dilution and 
of Triton X-100 on the accumufation of [3H]-(D-Ala2,D- 
Let?]-enkephalin ([3H]-DADL-enkephalin) within 
Torpedo synaptic vesicles. Uptake was performed at 
25°C using 2pM of the opioid peptide until a plateau 
was reached (t = 60 min), after which the vesicles were 
diluted 1 : 100 with either water, isotonic buffer (0.8 M 
glycine, 50 mM Hepes, pH 7.4), or isotonic buffer which 
contained Triton X- 100 (0. I To, w/v). The radioactivity 
retained within the vesicles 1 min after the dilution was 
determined by fjitratjon as described in section 2. 
Results presented are the mean + SD of 3 experiments. 
Control (100% = 2.8 f 0.7 pmollmg protein; n = 3) 
corresponds to the amount of [3H]-[D-AIa2,D-Leu5]- 
enkephalin taken up by the vesicles prior to the dilution. 
Results presented are the mean + SD of 3 experiments. 
These findings suggest hat [3H]-[D-Ala2,D-Leu5]- 
enkephalin is taken up into the vesicles by 
facilitated diffusion via a saturable transport 
system. 
The extent of [3HJ-[R-Ala2,D-LeusJ-enkephalin 
uptake, unlike its rate, did not saturate but rather 
increased linearly with the external ligand concen- 
tration (2-3OO/rM). Calculation of the in- 
travesicular concentration of i3Hf-[D-Ala2,D- 
Le&enkephalin from the amount of opioid pep- 
tide taken up by the vesicles (e.g., 2.9 + 
0.6 pmol/mg protein at 2 PM; n = 8) and from the 
known vesicular volume (3.8pl/mg protein) [6], 
yielded a value which was 2.5-fold lower than that 
of the external medium. This suggests that either 
the extent of uptake is coupled to a ther- 
modynamically limiting factor (e.g., A+ or ApH) 
or that T~r~~d~ synaptic vesicles are 
heterogeneous and contain subpopulations which 
differ in their ability to accumulate [3HJ-[D- 
Ala2,~-Leu5J~nkephalin~ The possibility that the 
opioid peptide is taken up by vesicles which differ 
completely from those which accumulate ACh is 
unlikely in view of the purity of the synaptic vesicle 
fraction [7], and the finding that the rates and ex- 
tents of [3H]-[D-Ala2,D-Leu5]-enkephalin uptake, 
like those of [3H]ACh [6], are highest in the 
purified synaptic vesicle fraction (e.g., at 2 PM 
[3H]-[D-Ala2,D-Leu5]-enkephalin, the specific 
rates and extents of uptake by the crude vesicular 
fraction P3 [7] are, respectively, 6 and IO-fold 
lower than those of the purified vesicles). 
The opiate receptor agonist morphine (IO~M~, 
and antagonist naloxone (IO~M) had virtually no 
effect on either the rate (94 + 15 and 120 1: 14% 
of control respectively; n = 2) or the extent (96 + 
20 and 102 ~fr 10% of control respectively; n = 2) 
of [3H]-[D-Ala2,D-LeuS]-enkephalin (2 PM) up- 
take. This suggests that the ligand recognition site 
of the vesicular transport system differs from that 
of the Torpedo presynaptic opiate receptor [lo). 
Fig.3. The dependence of the initial rate of [3H]-[D- 
Ala’,D-Let?]-enkephalin uptake ([3H]-DADL-enkepha- 
lin) by Torpedo synaptic vesicles on l&and 
concentration. Initial rates were calculated from the 
slopes of the linear phase (O-15 min) of uptake which 
was performed as described in section 2. Results 
presented are the mean + SD of 3 experiments. 
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The physiological role of the vesicular opioid 
transport system is not yet known. Preliminary 
studies indicate that ATP enhances the rate of 
[3H]-[D-Ala2,D-Leu5]-enkephalin uptake and that 
incubation of the vesicles with [3H]Leu-enkephaIin 
in the absence of peptidase inhibitors results in the 
uptake of both the intact peptide and its break- 
down products (in preparation). Thus, it is likely 
that the vesicular opioid peptide transport system, 
like the ACh carrier [5,6,11], is involved in 
reloading the vesicles following stimulation. 
However, the possibility that its function is to 
release endogenous vesicular peptides cannot be 
ruled out. Further studies of the uptake of intact 
and fragmented enkephalin into synaptic vesicles 
and isolated synaptosomes will undoubtedly fur- 
ther our understanding of the life cycle of opioid 
peptides in the Torpedo cholinergic nerve terminal. 
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